<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1817-5996</journal-id>
<journal-title><![CDATA[Revista Cubana de Reumatología]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Cuba Reumatol]]></abbrev-journal-title>
<issn>1817-5996</issn>
<publisher>
<publisher-name><![CDATA[Editorial CIMEQ]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1817-59962021000300010</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Patogenia de la artritis reumatoide, manejo terapéutico actual y perspectivas futuras]]></article-title>
<article-title xml:lang="en"><![CDATA[Pathogenesis of rheumatoid arthritis, current therapeutic management and future prospects]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Pino Falconí]]></surname>
<given-names><![CDATA[Pablo Ernesto]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Moya Romero]]></surname>
<given-names><![CDATA[Katherine Solange]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ramos Veintimilla]]></surname>
<given-names><![CDATA[Wendy Yadira]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Guevara Acurio]]></surname>
<given-names><![CDATA[Angela Lissette]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Básico de Pelileo  ]]></institution>
<addr-line><![CDATA[ Tungurahua]]></addr-line>
<country>Ecuador</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Puesto de Salud Mamayak  ]]></institution>
<addr-line><![CDATA[Morona Santiago]]></addr-line>
<country>Ecuador</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital General Docente Ambato  ]]></institution>
<addr-line><![CDATA[ Tungurahua]]></addr-line>
<country>Ecuador</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Centro de Salud de Pelileo Unidad Anidada ]]></institution>
<addr-line><![CDATA[ Tungurahua]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>23</volume>
<numero>3</numero>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1817-59962021000300010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1817-59962021000300010&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1817-59962021000300010&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN La artritis reumatoide es una enfermedad autoinmune, sistémica, crónica, que afecta con más frecuencia a mujeres que a hombres, y se observa predominantemente en ancianos. El propósito de este trabajo es presentar el resultado de una revisión bibliográfica sobre aspectos generales relacionados con la patogenia de la artritis reumatoide y el manejo terapéutico actual, así como perspectivas futuras de nuevos enfoques terapéuticos. Existen dos subtipos principales de artritis reumatoide según la presencia o ausencia de anticuerpos antiproteína citrulinada. La citrulinación es catalizada por la enzima peptidilarginina-deiminasa dependiente de calcio, que cambia una arginina cargada positivamente a una citrulina polar, pero neutra como resultado de una modificación postraduccional. Este estudio se enfoca en el subconjunto de artritis reumatoide positivo para anticuerpos antiproteína citrulinada y se divide la progresión del proceso de artritis reumatoide en varias etapas. Cabe mencionar que estas etapas pueden ocurrir de forma secuencial o simultánea. Se requiere con urgencia una mejor comprensión de cómo los mecanismos patológicos impulsan el deterioro del progreso de la artritis reumatoide en los individuos con el fin de desarrollar terapias que tratarán eficazmente a los pacientes en cada etapa del progreso de la enfermedad.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Rheumatoid arthritis is a chronic systemic autoimmune disease that arises more frequently in women than in men, and is predominantly observed in the elderly. To present the result of a bibliographic review on general aspects related to the pathogenesis of rheumatoid arthritis and current therapeutic management, as well as future perspectives of new therapeutic approaches. There are two main subtypes of rheumatoid arthritis according to the presence or absence of anti-citrullinated protein antibodies. Citrullination is catalyzed by the calcium-dependent enzyme peptidylarginine deiminase, which changes a positively charged arginine to a polar but neutral citrulline as a result of post-translational modification. This work focuses on the anti-citrullinated protein antibodies -positive rheumatoid arthritis subset and divides the progression of the rheumatoid arthritis process into several stages. It should be mentioned that these stages can occur sequentially or simultaneously. A better understanding of how pathological mechanisms drive the deterioration of rheumatoid arthritis progression in individuals is urgently required in order to develop therapies that will effectively treat patients at each stage of disease progression.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[patogenia de la artritis reumatoide]]></kwd>
<kwd lng="es"><![CDATA[subtipos principales]]></kwd>
<kwd lng="es"><![CDATA[manejo terapéutico actual]]></kwd>
<kwd lng="es"><![CDATA[perspectivas futuras]]></kwd>
<kwd lng="en"><![CDATA[pathogenesis of rheumatoid arthritis]]></kwd>
<kwd lng="en"><![CDATA[main subtypes]]></kwd>
<kwd lng="en"><![CDATA[current therapeutic management]]></kwd>
<kwd lng="en"><![CDATA[future perspectives]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Silman]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Pearson]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology and genetics of rheumatoid arthritis]]></article-title>
<source><![CDATA[Arthritis Res]]></source>
<year>2002</year>
<volume>4</volume>
<numero>^s3</numero>
<issue>^s3</issue>
<supplement>3</supplement>
<page-range>S265-72</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cho]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Factors associated with time to diagnosis from symptom onset in patients with early rheumatoid arthritis]]></article-title>
<source><![CDATA[Korean J Intern Med]]></source>
<year>2017</year>
<volume>113</volume>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raza]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Delays in assessment of patients with rheumatoid arthritis: variations across Europe]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2018</year>
<volume>70</volume>
<page-range>1822-5</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ometto]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Methods used to assess remission and low disease activity in rheumatoid arthritis]]></article-title>
<source><![CDATA[Autoimmun Rev]]></source>
<year>2017</year>
<volume>9</volume>
<page-range>161-4</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grennan]]></surname>
<given-names><![CDATA[DM]]></given-names>
</name>
<name>
<surname><![CDATA[Gray]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Loudon]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fear]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Methotrexate and early postoperative complications in patients with rheumatoid arthritis undergoing elective orthopaedic surgery]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2001</year>
<volume>60</volume>
<page-range>214-7</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bizzaro]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anti-cyclic citrullinated peptide antibody titer predicts time to rheumatoid arthritis onset in patients with undifferentiated arthritis: results from a 2-year prospective study]]></article-title>
<source><![CDATA[Arthritis Res Ther]]></source>
<year>2013</year>
<volume>15</volume>
<page-range>R16</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Padyukov]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2011</year>
<volume>70</volume>
<page-range>259-65</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Seegobin]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[ACPA-positive and ACPA-negative rheumatoid arthritis differ in their requirements for combination DMARDs and corticosteroids: secondary analysis of a randomized controlled trial]]></article-title>
<source><![CDATA[Arthritis Res Ther]]></source>
<year>2014</year>
<volume>16</volume>
<page-range>R13</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Raychaudhuri]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Five amino acids in three HLA proteins explain most of the association between MHC and seropositive rheumatoid arthritis]]></article-title>
<source><![CDATA[Nat Genet]]></source>
<year>2012</year>
<volume>44</volume>
<page-range>291-6</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Okada]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Risk for ACPA-positive rheumatoid arthritis is driven by shared HLA amino acid polymorphisms in Asian and European populations]]></article-title>
<source><![CDATA[Hum Mol Genet]]></source>
<year>2014</year>
<volume>23</volume>
<page-range>6916-26</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nabi]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Meta-analysis reveals PTPN22 1858C/T polymorphism confers susceptibility to rheumatoid arthritis in Caucasian but not in Asian population]]></article-title>
<source><![CDATA[Autoimmunity]]></source>
<year>2016</year>
<volume>49</volume>
<page-range>197-210</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Goh]]></surname>
<given-names><![CDATA[LL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NLRP1, PTPN22 and PADI4 gene polymorphisms and rheumatoid arthritis in ACPA-positive Singaporean Chinese]]></article-title>
<source><![CDATA[Rheumatol Int]]></source>
<year>2017</year>
<volume>37</volume>
<page-range>1295-302</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McCarthy]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Brief report: genetic variation of the alpha1 (antitrypsin gene is associated with increased autoantibody production in rheumatoid arthritis]]></article-title>
<source><![CDATA[Arthritis Rheumatol]]></source>
<year>2017</year>
<volume>69</volume>
<page-range>1576-9</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castaneda-Delgado]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Type I interferon gene response is increased in early and established rheumatoid arthritis and correlates with autoantibody production]]></article-title>
<source><![CDATA[Front Immunol]]></source>
<year>2017</year>
<volume>8</volume>
<page-range>285</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kuo]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Familial aggregation of rheumatoid arthritis and co-aggregation of autoimmune diseases in affected families: a nationwide population-based study]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2017</year>
<volume>56</volume>
<page-range>928-33</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[van der Woude]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gene-environment interaction influences the reactivity of autoantibodies to citrullinated antigens in rheumatoid arthritis]]></article-title>
<source><![CDATA[Nat Genet]]></source>
<year>2016</year>
<volume>42</volume>
<page-range>814-6</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Klareskog]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A new model for an etiology of rheumatoid arthritis: smoking may trigger HLA-DR (shared epitope)-restricted immune reactions to autoantigens modified by citrullination]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2006</year>
<volume>54</volume>
<page-range>38-46</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meng]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[DNA methylation mediates genotype and smoking interaction in the development of anti-citrullinated peptide antibody-positive rheumatoid arthritis]]></article-title>
<source><![CDATA[Arthritis Res Ther]]></source>
<year>2017</year>
<volume>19</volume>
<page-range>71</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Molecular insight into gut microbiota and rheumatoid arthritis]]></article-title>
<source><![CDATA[Int J Mol Sci]]></source>
<year>2016</year>
<volume>17</volume>
<page-range>431</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[An expansion of rare lineage intestinal microbes characterizes rheumatoid arthritis]]></article-title>
<source><![CDATA[Genome Med]]></source>
<year>2016</year>
<volume>8</volume>
<page-range>43</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gan]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The association between omega-3 fatty acid biomarkers and inflammatory arthritis in an anti-citrullinated protein antibody positive population]]></article-title>
<source><![CDATA[Rheumatology]]></source>
<year>2017</year>
<volume>56</volume>
<page-range>2229-36</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term dietary quality and risk of developing rheumatoid arthritis in women]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2017</year>
<volume>76</volume>
<page-range>1357-64</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pianta]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Two rheumatoid arthritis-specific autoantigens correlate microbial immunity with autoimmune responses in joints]]></article-title>
<source><![CDATA[J Clin Invest]]></source>
<year>2017</year>
<volume>127</volume>
<page-range>2946-56</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Edwards]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The nature and origins of synovium: experimental approaches to the study of synoviocyte differentiation]]></article-title>
<source><![CDATA[J Anat]]></source>
<year>1994</year>
<volume>184</volume>
<page-range>493-501</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sergijenko]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Roelofs]]></surname>
<given-names><![CDATA[AJ]]></given-names>
</name>
<name>
<surname><![CDATA[Riemen]]></surname>
<given-names><![CDATA[AH]]></given-names>
</name>
<name>
<surname><![CDATA[De Bari]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bone marrow contribution to synovial hyperplasia following joint surface injury]]></article-title>
<source><![CDATA[Arthritis Res Ther]]></source>
<year>2016</year>
<volume>18</volume>
<page-range>166</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sabeh]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Fox]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Weiss]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Membrane-type I matrix metalloproteinase dependent regulation of rheumatoid arthritis synoviocyte function]]></article-title>
<source><![CDATA[J Immunol]]></source>
<year>2010</year>
<volume>184</volume>
<page-range>6396-406</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[McInnes]]></surname>
<given-names><![CDATA[IB]]></given-names>
</name>
<name>
<surname><![CDATA[Schett]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The pathogenesis of rheumatoid arthritis]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2011</year>
<volume>65</volume>
<page-range>2205-19</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pap]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Korb-Pap]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cartilage damage in osteoarthritis and rheumatoid arthritis (two unequal siblings]]></article-title>
<source><![CDATA[Nat Rev Rheumatol]]></source>
<year>2015</year>
<volume>11</volume>
<page-range>606-15</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Arts]]></surname>
<given-names><![CDATA[EE]]></given-names>
</name>
<name>
<surname><![CDATA[Fransen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Den Broeder]]></surname>
<given-names><![CDATA[AA]]></given-names>
</name>
<name>
<surname><![CDATA[van Riel]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Popa]]></surname>
<given-names><![CDATA[CD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Low disease activity (DAS28&lt;/=3.2) reduces the risk of first cardiovascular event in rheumatoid arthritis: a time-dependent Cox regression analysis in a large cohort study]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2017</year>
<volume>76</volume>
<page-range>1693-9</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Myasoedova]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Total cholesterol and LDL levels decrease before rheumatoid arthritis]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2010</year>
<volume>69</volume>
<page-range>1310-4</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[YJ]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[YT]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[CB]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[CY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The risk of cancer in patients with rheumatoid arthritis: a nationwide cohort study in Taiwan]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2011</year>
<volume>63</volume>
<page-range>352-8</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deane]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Can rheumatoid arthritis be prevented? Best Pract]]></article-title>
<source><![CDATA[Res Clin Rheumatol]]></source>
<year>2013</year>
<volume>27</volume>
<page-range>467-85</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Finckh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Liang]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[van Herckenrode]]></surname>
<given-names><![CDATA[CM]]></given-names>
</name>
<name>
<surname><![CDATA[de Pablo]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a metaanalysis]]></article-title>
<source><![CDATA[Arthritis Rheum]]></source>
<year>2006</year>
<volume>55</volume>
<page-range>864-72</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fuchs]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Kaye]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Callahan]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Nance]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Pincus]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease]]></article-title>
<source><![CDATA[J Rheumatol]]></source>
<year>1989</year>
<volume>16</volume>
<page-range>585-91</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Naldini]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Gene therapy returns to centre stage]]></article-title>
<source><![CDATA[Nature]]></source>
<year>2015</year>
<volume>526</volume>
<page-range>351-60</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Notch1 targeting siRNA delivery nanoparticles for rheumatoid arthritis therapy]]></article-title>
<source><![CDATA[J Control Release]]></source>
<year>2015</year>
<volume>216</volume>
<page-range>140-8</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lee]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TNF-alpha gene silencing using polymerized siRNA/thiolated glycol chitosan nanoparticles for rheumatoid arthritis]]></article-title>
<source><![CDATA[Mol Ther]]></source>
<year>2014</year>
<volume>22</volume>
<page-range>397-408</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lundstrom]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[IgG Fc galactosylation predicts response to methotrexate in early rheumatoid arthritis]]></article-title>
<source><![CDATA[Arthritis Res Ther]]></source>
<year>2017</year>
<volume>19</volume>
<page-range>182</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Whang]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Chang]]></surname>
<given-names><![CDATA[BY]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bruton&#8217;s tyrosine kinase inhibitors for the treatment of rheumatoid arthritis]]></article-title>
<source><![CDATA[Drug Discov Today]]></source>
<year>2014</year>
<volume>19</volume>
<page-range>1200-4</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alvaro-Gracia]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intravenous administration of expanded allogeneic adipose- derived mesenchymal stem cells in refractory rheumatoid arthritis (Cx611): results of a multicentre, dose escalation, randomised, single-blind, placebo-controlled phase Ib/IIa clinical trial]]></article-title>
<source><![CDATA[Ann Rheum Dis]]></source>
<year>2017</year>
<volume>76</volume>
<page-range>196-202</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
